The Department has played the role of an innovative translational research institution based on industry-university-research institute cooperation.
The Department is making efforts to become a world-class new drug research institution by developing innovative basic technologies and establishing a next-generation new drug pipeline of an international level.
Director
NameHwan Jung Lim
Office+82-42-860-7177
E-mailindium@krict.re.kr
Hwan Jung Lim
Major research fields
Development of new drug solution based on artificial intelligence and big data
Development of innovative drug based on precision medicine
Development of novel-concept disease treatment technology based on targeting chimera (TAC) technology
Establishment of efficacy/drugability evaluation platform for biological model-based disease treatment drugs
Research on development of rare disease targets and therapeutics
Major research accomplishments
Securing artificial intelligence-based toxicity/drugability prediction system and Drug Rescue technology based on the system
Securing patient-derived big data analysis-based solution for innovative new drug target discovery, biomarker prediction, and verification
Development of candidates of precision medicine-based anticancer agents against intractable cancers; technology transfer; and entry into clinical study
Establishment of proteolytic agent (PROTAC and molecular glue) library and securing of leading materials
Establishment of 3D biological model-based system for evaluating drug efficacy on brain diseases
Discovery and verification of rare disease targets and development of therapeutics